Table 2.
FACS analysis of tumour-infiltrating leukocyte (TIL) populations from CT26 tumour-bearing mice at day 14 post-induction of ICI monotherapy or combination therapies. Percentages of T cell subpopulations across control groups, treatment responder (TR) arms, and all treatment non-responders (TNR) across all treatment arms. Data are shown as mean % of cells ± S.D. and are representative of n = 5–10 mice/ group, *P < 0.05; **P < 0.01, ***P < 0.001, comparing TR to TNR
| CT26 | |||
|---|---|---|---|
| CD3+ % of CD45+ | CD8+ % of CD3+ | CD8+ GZB+ % of GZB+ | |
| Control | 28.6 ± 4.4 | 10.4 ± 1.0 | 12.1 ± 2.4 |
| TR | |||
| αPD1 | 36.2 ± 5.7* | 20.7 ± 4.0* | 28.2 ± 1.8** |
| αCTLA4 | 42.8 ± 8.6* | 26.5 ± 3.7** | 40.4 ± 11.8** |
| αPD1 + αCTLA4 | 50.6 ± 8.0** | 32.4 ± 7.8*** | 58.6 ± 5.5*** |
| αOX40 | 54.5 ± 12.0** | 43.7 ± 5.6*** | 67.8 ± 5.6*** |
| αPD1 + αOX40 | 56.7 ± 7.8** | 48.6 ± 5.7*** | 64.7 ± 13.1** |
| αTIM3 | 35.4 ± 6.9 | 19.0 ± 3.9 | 9.7 ± 2.8 |
| αPD1 + αTIM3 | 34.7 ± 4.9 | 19.9 ± 5.0 | 13.9 ± 6.7 |
| αLAG3 | 39.3 ± 11.0 | 20.6 ± 7.3 | 12.9 ± 3.0 |
| αPD1 + αLAG3 | 35.9 ± 8.1 | 18.0 ± 6.9 | 12.0 ± 3.3 |
| TNR | 29.4 ± 3.1 | 11.4 ± 0.9 | 11.8 ± 1.3 |